Anti-HPVHIV human body lubricating liquid

Abstract

The present invention discloses an anti-HPVHIV human body lubricating liquid, and relates to the technical field of biological medicine, the anti-HPVHIV human body lubricating liquid is prepared from the following raw materials by weight: 0.1-20 parts of sodium hyaluronate with a molecular weight of 10,000-25,000 Da; 20 to 99 parts of purified water; 0.01 to 10 parts of sodium dihydrogen phosphate; 1 to 10 parts of water; 0.1 to 20 parts of glycerol; 0.01 to 10 parts of a surfactant; the surfactant is one or more of betaine, lauryl sodium sulfate and Tween 80, and the molecular weight of the sodium hyaluronate is 0.5 million to 1.5 million Da. The anti-HPVHIV human body lubricating liquid has dual effects, on one hand, a physical membrane is formed through sodium hyaluronate, and HPV viruses and HIV viruses are prevented from infiltrating host cells of a vaginal mucosa base layer;

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of biological medicine, in particular to an anti-HPV HIV human body lubricant. BACKGROUND

[0002] With China entering an aging society, the proportion of the elderly population is gradually increasing, and the sexual health problems of elderly couples are increasingly prominent. Many elderly women enter menopause, resulting in a decrease in vaginal secretions, leading to an unsuitable sexual life, while some elderly men still have sexual needs. This physiological difference affects the quality of life of elderly couples.

[0003] In terms of women's reproductive health, cervical cancer is one of the malignant tumors that seriously threaten women's health. In China, the number of new cases of cervical cancer accounts for 73% to 93% of the incidence rate of female reproductive system malignant tumors. Research has confirmed that the main pathogenic factor of cervical cancer is persistent infection of high-risk HPV, and there are more than 130 different subtypes of HPV virus, of which high-risk HPV types 16 and 18 are the main types causing more than 90% of cervical cancer. At the same time, relevant data show that in the transmission route, the number of HPV / HIV virus particles in the semen and vaginal secretions of infected people reaches 11,000 and 7,000 per milliliter, respectively, with extremely high transmission intensity.

[0004] At present, there is no specific treatment drug for gynecological diseases caused by HPV virus infection, and the common treatment method is local drug treatment, such as using interferon, biological protein preparation, traditional Chinese medicine, etc. through vaginal administration, but these drug preparations affect the efficacy due to texture or their own defects during use, and cannot well eliminate HPV virus. The conventional anti-HPV dressing mainly uses film-forming property to block the virus at the physical level, and the antibacterial agent used cannot effectively kill the virus. SUMMARY

[0005] In view of the deficiencies of the prior art, the present application provides an anti-HPV HIV human body lubricant, which solves the problems raised in the background art.

[0006] To achieve the above purpose, the present application realizes the following technical scheme: an anti-HPV HIV human body lubricant is made of the following raw materials by weight: 0.1-20 parts of sodium hyaluronate with a molecular weight of 10,000-2.5 million Da; 20-99 parts of purified water; 0.01-10 parts of sodium dihydrogen phosphate; 1-10 parts of water; 0.1-20 parts of glycerol; 0.01-10 parts of a surfactant; and 0.01-10 parts of a 0.1%-20% sodium hypochlorite solution.

[0007] Further, the surfactant is one or more of betaine, sodium dodecyl sulfate, and Tween 80.

[0008] Further, the sodium hyaluronate has a molecular weight of 500,000-1,500,000 Da.

[0009] Further, the sodium hypochlorite solution has a concentration of 1%-10%.

[0010] Further, the preparation method comprises the following steps: (1) adding 0.1-20 parts of sodium hyaluronate with a molecular weight of 10,000-25,000,000 Da into 20-99 parts of purified water, heating to 40-80℃ and stirring for 2-8 hours; (2) adding 0.01-10 parts of sodium dihydrogen phosphate into 1-10 parts of water, heating to 40-80℃ and stirring for 1-30 minutes; (3) adding the solution in step (2) into the solution in step (1) and cooling; (4) adding 0.1-20 parts of glycerol and 0.01-10 parts of a surfactant into the solution in step (3) and stirring uniformly; (5) adding 0.01-10 parts of a sodium hypochlorite solution with a concentration of 0.1%-20% into the solution in step (4) and stirring uniformly; (6) filling the solution in step (5) and processing to complete.

[0011] Further, the heating temperature in step (1) and step (2) is 60-70℃.

[0012] Further, the stirring time in step (1) is 2-4 hours.

[0013] Further, the stirring time in step (2) is 10-20 minutes.

[0014] The application provides an anti-HPV HIV human body lubricant, which has the following beneficial effects: the anti-HPV HIV human body lubricant has a double effect, on one hand, a physical film is formed by sodium hyaluronate to block HPV virus and HIV virus from infiltrating host cells in the vaginal mucosa base layer, on the other hand, disinfecting components such as sodium hypochlorite in the anti-HPV HIV human body lubricant can effectively kill HPV high-risk viruses and HIV viruses, reduce the number of virus particles in semen and vaginal secretions, so as to achieve the purpose of blocking infection, and compared with the existing dressing which only has a physical blocking function, the anti-virus effect is more remarkable.

[0015] The added sodium dihydrogen phosphate as a stabilizer can ensure the stability of disinfecting components such as sodium hypochlorite, solve the problem that products containing such disinfecting components cannot be stored for a long time, and prolong the shelf life of the product. DETAILED DESCRIPTION

[0016] The embodiments of the present application will be further described in conjunction with the following examples. The following examples are intended to illustrate the present application and should not be used to limit the scope of the present application.

[0017] Example 1 (1) 1.2 parts of sodium hyaluronate with a molecular weight of 1.2 million Da was added to 73.6 parts of purified water, heated to 70°C and stirred for 2 h to be uniformly transparent; (2) 0.8 parts of sodium dihydrogen phosphate was added to 10 parts of water, heated to 70°C, and stirred for 20 min to be dissolved; (3) The solution of step (2) was added to the solution of step (1) and cooled; (4) 10 parts of glycerol, 1.0 part of betaine were added to the solution of step (3) and stirred uniformly; (5) 0.8 parts of sodium hypochlorite solution with a concentration of 5% was added to the solution of step (4) and stirred uniformly; (6) The solution of step (5) was filled and the processing was completed.

[0018] Example 2 (1) 0.5 parts of sodium hyaluronate with a molecular weight of 0.5 million Da was added to 80 parts of purified water, heated to 60°C and stirred for 3 h to be uniformly transparent; (2) 0.5 parts of sodium dihydrogen phosphate was added to 5 parts of water, heated to 60°C, and stirred for 10 min to be dissolved; (3) The solution of step (2) was added to the solution of step (1) and cooled; (4) 12 parts of glycerol, 0.5 parts of sodium dodecyl sulfate were added to the solution of step (3) and stirred uniformly; (5) 1.0 parts of sodium hypochlorite solution with a concentration of 3% was added to the solution of step (4) and stirred uniformly; (6) The solution of step (5) was filled and the processing was completed.

[0019] Example 3 (1) 5 parts of sodium hyaluronate with a molecular weight of 1.5 million Da was added to 60 parts of purified water, heated to 65°C and stirred for 4 h to be uniformly transparent; (2) 2 parts of sodium dihydrogen phosphate was added to 8 parts of water, heated to 65°C, and stirred for 15 min to be dissolved; (3) The solution of step (2) was added to the solution of step (1) and cooled; (4) 15 parts of glycerol, 2 parts of Tween 80 were added to the solution of step (3) and stirred uniformly; (5) 3 parts of sodium hypochlorite solution with a concentration of 8% was added to the solution of step (4) and stirred uniformly; (6) the solution of step (5) is filled and processed to complete.

[0020] The human body lubricant prepared by the above-mentioned embodiments 1-3 is tested for antiviral performance, and the results show that the killing rates of HPV16, HPV18 and HIV viruses are all above 99%; meanwhile, stability test is carried out, and after being stored at normal temperature for 12 months, the content of the disinfecting component can still maintain more than 90% of the initial content, which shows that the product has good antiviral effect and stability.

[0021] The embodiments of the present application are given for the purpose of illustration and description, and are not intended to be exhaustive or to limit the present application to the disclosed form. Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiments are chosen and described in order to best explain the principles of the present application and its practical application, and to enable others skilled in the art to understand the present application for various embodiments with various modifications as are suited to the particular use contemplated.

Claims

1. An anti-HPV / HIV human lubricant, characterized in that: It is made from the following raw materials in parts by weight: 0.1 to 20 parts of sodium hyaluronate with a molecular weight of 10,000 to 2,500,000 Da; 20 to 99 parts of purified water; 0.01 to 10 parts of sodium dihydrogen phosphate; 1 to 10 parts of water; 0.1 to 20 parts of glycerol; 0.01 to 10 parts of surfactant; and 0.01 to 10 parts of sodium hypochlorite solution with a concentration of 0.1% to 20%.

2. The anti-HPV / HIV human lubricant according to claim 1, characterized in that: The surfactant is one or more of betaine, sodium lauryl sulfate, and Tween 80.

3. The anti-HPV / HIV human lubricant according to claim 2, characterized in that: The molecular weight of the sodium hyaluronate is 500,000 to 1,500,000 Da.

4. The anti-HPV / HIV human lubricant according to claim 3, characterized in that: The concentration of the sodium hypochlorite solution is 1% to 10%.

5. The anti-HPV / HIV human lubricant according to claim 4, characterized in that: Its preparation method includes the following steps: (1) Add 0.1 to 20 parts of sodium hyaluronate with a molecular weight of 10,000 to 2,500,000 Da to 20 to 99 parts of purified water, heat to 40 to 80°C and stir for 2 to 8 hours; (2) Add 0.01 to 10 parts of sodium dihydrogen phosphate to 1 to 10 parts of water, heat to 40 to 80°C, and stir for 1 to 30 minutes; (3) Add the solution from step (2) to the solution from step (1) and cool down; (4) Add 0.1 to 20 parts of glycerol and 0.01 to 10 parts of surfactant to the solution in step (3) and stir until homogeneous; (5) Add 0.01 to 10 parts of sodium hypochlorite solution with a concentration of 0.1% to 20% to the solution in step (4) and stir until homogeneous; (6) Fill the solution from step (5) to complete the processing.

6. The anti-HPV / HIV human lubricant according to claim 5, characterized in that: The heating temperature in steps (1) and (2) is 60-70℃.

7. The anti-HPV / HIV human lubricant according to claim 6, characterized in that: The stirring time in step (1) is 2 to 4 hours.

8. The anti-HPV / HIV human lubricant according to claim 7, characterized in that: The stirring time in step (2) is 10 to 20 minutes.